| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
TRAP1 79 nM (IC50); HSP90 698 nM (IC50)
TRAP1 (Tumor Necrosis Factor Receptor-Associated Protein 1), a mitochondrial chaperone protein that is often upregulated in cancer cells to protect them from oxidative stress. DN401 also weakly inhibits Hsp90 (IC50 = 698 nM), but its high selectivity for TRAP1 makes it a valuable tool for studying the specific role of TRAP1 in cancer cell metabolism and survival. |
|---|---|
| ln Vitro |
DN401 (5-20 µM; 24 hours) has excellent cancer-specific cytotoxicity, but has reduced cytotoxicity in normal cells[1]. DN401 (20 µM; 6 hours) inhibits the expression of Chk1 and Akt in HeLa cells[1].
DN401 is a potent TRAP1 inhibitor with an IC50 of 79 nM and shows a weak inhibition of Hsp90 with an IC50 of 698 nM. It shows excellent cancer-specific cytotoxicity (5-20 uM) but has reduced cytotoxicity in normal cells. DN401 (20 uM; 6 hours) inhibits the expression of certain mitochondrial proteins and disrupts cancer cell metabolism. This targeted effect is what drives its potent anticancer activity. |
| ln Vivo |
DN401 (30 mg/kg; intraperitoneal injection; once a day; for 14 days) reduced tumor growth and increased apoptosis in tumor tissues without causing weight loss or histological abnormalities [1].
No specific in vivo data was found for DN401. Given its potent and selective inhibition of mitochondrial TRAP1 and its strong cancer-specific cytotoxicity in vitro, DN401 is expected to have significant antitumor activity in vivo. Researchers can use this compound to validate TRAP1 as a target and to demonstrate proof-of-concept for a new class of anticancer drugs. |
| Enzyme Assay |
Standard TRAP1 ATPase activity assay: Recombinant human TRAP1 protein is incubated in an assay buffer with ATP and a fluorogenic or luminescent ATPase detection reagent. Serial dilutions of DN401 are added to the reaction. The change in luminescence or fluorescence signal, which is proportional to the amount of ATP hydrolyzed, is measured. The IC50 for DN401 is calculated to be 79 nM.
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: HeLa, SK-HEP-1, T98G, H460, and PC3 cells Tested Tested Concentrations: 5 µM, 10 µM, 15 µM, 20 µM Incubation Duration: 24 hours Experimental Results: Exhibited cytotoxic activity. Western Blot Analysis[1] Cell Types: HeLa cells Tested Tested Concentrations: 20 µM Incubation Duration: 6 hours Experimental Results: Inhibited the expression of Chk1 and Akt. Standard cancer cell viability assay: A panel of cancer cell lines (e.g., HCT116, HeLa) are seeded in 96-well plates. After attachment, cells are treated with increasing concentrations of DN401 (e.g., 1, 5, 10, 20 uM) for 24-72 hours. Cell viability is measured using a CellTiter-Glo luminescent cell viability assay. The GI50 (50% growth inhibition) is calculated. A parallel assay on normal fibroblasts can be used to demonstrate the cancer-specific cytotoxicity of DN401. |
| Animal Protocol |
Animal/Disease Models: 6-week-old BALB/c nu/nu male mice injected with PC3 cells[1]
Doses: 30 mg/kg Route of Administration: ip; once daily; for 14 days Experimental Results: Reduced tumor growth. No specific animal protocol was found. To evaluate the in vivo efficacy of DN401, a xenograft mouse model would be used. For example, 5×10⁶ HCT116 colorectal cancer cells are injected subcutaneously into BALB/c nude mice. Once tumors reach an average size of 150 mm3, mice are randomized to receive DN401 (e.g., 10 or 30 mg/kg) or vehicle by intraperitoneal (IP) injection. Tumor volume is measured twice weekly. The percent tumor growth inhibition (TGI) is calculated at the end of the study. |
| ADME/Pharmacokinetics |
No specific PK data was found. DN401 is a small molecule with a molecular weight of 382.60, which is favorable for oral absorption. However, its PK parameters (absorption, half-life, clearance, bioavailability) have not been reported. As a research compound, it is typically administered by intraperitoneal (IP) injection for in vivo studies.
|
| Toxicity/Toxicokinetics |
No specific toxicity data was found. DN401 shows reduced cytotoxicity in normal cells compared to cancer cells, suggesting it may have a favorable therapeutic window. However, extensive preclinical safety studies are required. Potential toxicities could arise from inhibiting the mitochondrial stress response in highly metabolically active normal tissues like the heart, liver, and kidney.
|
| References | |
| Additional Infomation |
DN401 (CAS: 2135749-60-7) has a molecular formula of C13H9BrClN5O2 and a molecular weight of 382.60. It is a potent TRAP1 inhibitor with an IC50 of 79 nM and shows potent anticancer activity. It appears as an off-white to light-yellow solid powder. For research use only.
|
| Molecular Formula |
C13H9BRCLN5O2
|
|---|---|
| Molecular Weight |
382.60
|
| CAS # |
2135749-60-7
|
| Appearance |
Off-white to light yellow solid powder
|
| SMILES |
BrC1C=C2C(=CC=1CN1C3C(=C(N=C(N)N=3)Cl)C=N1)OCO2
|
| Synonyms |
Panvotinib-401; Pan-401
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~17.5 mg/mL (~45.74 mM; with ultrasonication (<60°C))
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6137 mL | 13.0685 mL | 26.1370 mL | |
| 5 mM | 0.5227 mL | 2.6137 mL | 5.2274 mL | |
| 10 mM | 0.2614 mL | 1.3068 mL | 2.6137 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
